For the twelve months ended Sep 30, 2026, NovoCure Limited reported $725.39M of revenue and -$121.73M of net income.
NVCR revenueQ3 2026$193.40M
- Quarter YoY
- +15.7%
- QoQ
- +5.3%
- FY YoY
- +8.3%
- 5Y CAGR
- +5.8%
- 10Y CAGR
- +34.8%
NVCR revenue was $193.40M in fiscal Q3 2026 (ended Sep 30, 2026), up 15.7% from a year earlier and up 5.3% from the prior quarter. For the full fiscal 2025 it was $655.35M, up 8.3% from fiscal 2024. Compound annual growth was +5.8% over 5 years and +34.8% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 13 fiscal years on file.
NVCR net incomeQ3 2026-$10.44M
NVCR net income was -$10.44M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$37.27M a year earlier. For the full fiscal 2025 it was -$136.23M, compared with -$168.63M in fiscal 2024.
NVCR EPSQ3 2026-$0.09
NVCR diluted EPS was -$0.09 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.33 a year earlier. For the full fiscal 2025 it was -$1.22, compared with -$1.56 in fiscal 2024.
NVCR free cash flowQ3 2026$15.75M
- Quarter YoY
- +5.5%
- QoQ
- 13x
NVCR free cash flow was $15.75M in fiscal Q3 2026 (ended Sep 30, 2026), up 5.5% from a year earlier and up about 13-fold from the prior quarter. For the full fiscal 2025 it was -$75.68M, compared with -$69.22M in fiscal 2024.
Source: XBRL data NovoCure Limited files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.